NEWSROOM

Pharmaceutical

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Pittsburgh, PA, April 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel...

read more
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

Pittsburgh, PA, April 03, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for the evaluation of LP-10, an intravesical liposomal formulation of tacrolimus, as a potential treatment for...

read more
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

Clinical testing of LP-410 expected to commence in Q2 2024 Pittsburgh, PA, March 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GVHD). Lipella’s...

read more
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company’s lead candidate, LP-10 Pittsburgh, PA, February 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference’s key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET....

read more
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

-Lipella Granted Two Orphan Drug Designations by FDA- Pittsburgh, PA, December 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations...

read more
FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

NEW YORK, NY, December 13, 2023 - ReShape Lifesciences (Nasdaq: RSLS) has been granted FDA approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX. The company’s share price surged 100% in trading on Wednesday morning. https://prismmarketview.com/companies/reshape-lifesciences-inc/ Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, said, “PMA supplement approval for our next generation Lap-Band® 2.0 FLEX is a...

read more
PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

NEW YORK, NY, December 13, 2023 - Quoin Pharmaceuticals (Nasdaq: QNRX) has received U.S. Food and Drug Administration (FDA) clearance to implement several protocol amendments to its two ongoing clinical trials for QRX003, which is a potential treatment for Netherton Syndrome, a rare genetic skin disease for which there is no cure and no approved treatments. These protocol amendments are being implemented with a view to generating an even more robust data set and potentially more...

read more
MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024

MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024

NEW YORK, NY, December 11, 2023 - The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a  Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA). The company plans to launch the trial in the first quarter of 2024. Chris Chapman, M.D., president, director, and chief medical officer of MyMD Pharmaceuticals, said, “With the FDA’s recent clearance of our IND in RA, we are moving forward with plans to...

read more
PRISM MarketView Biotech Index Top Mover Spotlight: Kamada (KMDA)

PRISM MarketView Biotech Index Top Mover Spotlight: Kamada (KMDA)

NEW YORK, NY, December 07, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Kamada Ltd. (Nasdaq: KMDA), a commercial-stage global biopharmaceutical company with a portfolio of products for rare and serious conditions and a leader in the specialty plasma-derived field, today announced it has inked its largest commercial agreement to date, set to take effect in January 2024. https://prismmarketview.com/companies/kamada-ltd/...

read more
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

WARREN, N.J., Nov. 29, 2023 -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the “NYSE Regulation”) has determined to immediately suspend trading in the Company’s common stock from NYSE American, LLC (the “NYSE American”). As previously disclosed, the NYSE...

read more
PRISM MediaWire – Weekly Press Resume – Nov. 13 to Nov. 17, 2023

PRISM MediaWire – Weekly Press Resume – Nov. 13 to Nov. 17, 2023

New York, Nov. 17, 2023 PRISM MediaWire - Weekly Press Resume Nov. 13 to Nov. 17, 2023 Ethical Web AI Launches AI Seek 4.0 with Almost Real-Time Data https://prismmediawire.com/ethical-web-ai-launches-ai-seek-4-0-with-almost-real-time-data/ AmpliTech to Host Quarterly Investor Call to Review Q3 2023 Earnings on Tuesday November 14, 4:30 PM ET; Dial-in # 1-833-630-0019 or 1-412-317-1807...

read more
PRISM MediaWire – Weekly Press Resume – Nov. 13 to Nov. 17, 2023

PRISM MediaWire – Weekly Press Resume – Nov. 6 to Nov. 10, 2023

New York, New York, Nov. 10, 2023 PRISM MediaWire - Weekly Press Resume Nov. 6 to Nov. 10, 2023 Two Hands Corporation Launches Sports Illustrated Line Protein Bars in Canada https://prismmediawire.com/two-hands-corporation-launches-sports-illustrated-line-protein-bars-in-canada/ BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023...

read more
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug

“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.” Dr. Michael Chancellor, Chief Medical Officer at Lipella Pharmaceuticals Pittsburgh, PA, November 10, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), has received Orphan Drug Designation for its LP-310 drug candidate for oral...

read more
PRISM MediaWire – Weekly Press Resume – Oct. 30 to Nov. 3, 2023

PRISM MediaWire – Weekly Press Resume – Oct. 30 to Nov. 3, 2023

New York, New York, Nov. 3, 2023 PRISM MediaWire - Weekly Press Resume Oct. 30 to Nov. 3, 2023 Metatron Pioneers Real-Time Stock Insights with AI-Enhanced Stock Trendz https://prismmediawire.com/metatron-pioneers-real-time-stock-insights-with-ai-enhanced-stock-trendz/ PRISM MarketView Highlights Its Spooktacular Zombie Index For Halloween https://prismmediawire.com/prism-marketview-highlights-its-spooktacular-zombie-index-for-halloween/ Franklin Mining Bolivia (a branch of Franklin Mining,...

read more
PRISM MediaWire – Weekly Press Resume – Oct. 23 to Oct. 27, 2023

PRISM MediaWire – Weekly Press Resume – Oct. 23 to Oct. 27, 2023

New York, New York, October 27, 2023 PRISM MediaWire - Weekly Press Resume Oct. 23 to Oct. 27, 2023 Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference https://prismmediawire.com/lipella-pharmaceuticals-to-present-at-the-fall-foliage-microcap-rodeo-conference/ Metatron Partners with MML Marketing, Boasting a Proven Track Record of $19M in Sales https://prismmediawire.com/metatron-partners-with-mml-marketing-boasting-a-proven-track-record-of-19m-in-sales/ Argentum...

read more
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference

Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference

Pittsburgh, PA, October 23, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th - 27th. Dr. Jonathan Kaufman, CEO of Lipella, said: “2023 continues to be a year of significant milestone achievements for Lipella. Early in the year, we were delighted to report...

read more

Categories

Loading
Translate »